Evidence map›Paper›PMID 39542140›Full record

ArticleAntiviral research2024

Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.

Stephen R Welch, John P Bilello, Kara Carter, Leen Delang, Larissa Dirr, David Durantel, Joy Y Feng, Brian B Gowen, Lara J Herrero, Zlatko Janeba and 9 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Stephen R WelchViral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: swelch1@cdc.gov.
John P BilelloGilead Sciences, Inc., Foster City, CA, USA.
Kara CarterEvotec US, Princeton, NJ, USA.
Leen DelangVirus-Host Interactions & Therapeutic Approaches Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Larissa DirrInstitute for Biomedicine and Glycomics, Griffith University, Southport, QLD, Australia.
David DurantelCentre International de Recherche en Infectiologie (CIRI), Inserm_U1111, CNRS_UMR5308, Université Claude Bernard Lyon 1, F-69007, Lyon, France.
Joy Y FengDivision of the Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Brian B GowenInstitute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT, USA.
Lara J HerreroInstitute for Biomedicine and Glycomics, Griffith University, Southport, QLD, Australia.
Zlatko JanebaInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 160 00, Prague, Czech Republic.
Gerald KleymannInnovative Molecules GmbH, Lipowsky Str. 10, 81373, Munich, Bavaria, Germany.
Alpha A LeePostEra Inc, 1 Broadway, Cambridge, MA, USA.
Chris MeierOrganic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Martin-Luther-King-Platz 6, Hamburg, Germany.
Jennifer MoffatDepartment of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.
Luis M SchangBaker Institute and Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
Joshua T SchifferFred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, WA, USA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Katherine L Seley-RadtkeDepartment of Chemistry & Biochemistry, University of Maryland, Baltimore County, Baltimore, MD, USA.
Timothy P SheahanDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jessica R SpenglerViral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: jspengler@cdc.gov.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

The 37th International Conference on Antiviral Research (ICAR) was held in Gold Coast, Australia, May 20-24, 2024. ICAR 2024 featured over 75 presentations along with two poster sessions and special events, including those specifically tailored for trainees and early-career scientists. The meeting served as a platform for the exchange of cutting-edge research, with presentations and discussions covering novel antiviral compounds, vaccine development, clinical trials, and therapeutic advancements. A comprehensive array of topics in antiviral science was covered, from the latest breakthroughs in antiviral drug development to innovative strategies for combating emerging viral threats. The keynote presentations provided fascinating insight into two diverse areas fundamental to medical countermeasure development and use, including virus emergence at the human-animal interface and practical considerations for bringing antivirals to the clinic. Additional sessions addressed a variety of timely post-pandemic topics, such as the hunt for broad spectrum antivirals, combination therapy, pandemic preparedness, application of in silico tools and AI in drug discovery, the virosphere, and more. Here, we summarize all the presentations and special sessions of ICAR 2024 and introduce the 38th ICAR, which will be held in Las Vegas, USA, March 17-21, 2025.

Indexed as

Antiviral AgentsAnimalsAustraliaCOVID-19COVID-19 Drug TreatmentDrug DevelopmentDrug DiscoveryHumansVaccine DevelopmentAntiviral Agents

Identifiers

PMID39542140
PMCPMC11871649

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.